Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

21. Clinically Localized Prostate Cancer

Clinically Localized Prostate Cancer ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2018

23. Prostate cancer

Prostate cancer Prostate cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Prostate cancer Last reviewed: September 2018 Last updated: September 2018 Important updates Safety concerns prompt EMA to restrict the use of radium-223 in metastatic prostate cancer New restrictions have been placed on the use of radium-223 for the treatment of metastatic prostate cancer following a safety review by the European (...) Medicines Agency (EMA). The review concluded that the use of radium-223 is associated with an increased risk of fractures and a possible increased risk of death. The EMA has imposed the following new restrictions on the use of radium-223: Restrict use to patients who have received two prior treatments for metastatic prostate cancer, or who cannot receive other treatments Do not use with abiraterone and prednisolone (this combination is contraindicated) Do not use with other systemic cancer therapies

BMJ Best Practice2018

24. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. OBJECTIVE: To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018 (...) . ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSA screening with usual care in men without a diagnosis of prostate cancer. DATA EXTRACTION: At least two reviewers screened studies, extracted data, and assessed the quality of eligible studies. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including selection of outcomes important to patients. We used a random effects model to obtain

BMJ2018

25. Prostate Cancer

Prostate Cancer Prostate Cancer | Uroweb Guidelines › Prostate Cancer Prostate Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . EAU Central Office PO Box 30016 NL-6803 AA ARNHEM The Netherlands

European Association of Urology2018

27. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial 29980331 2018 07 07 1873-7560 2018 Jul 03 European urology Eur. Urol. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. S0302-2838(18)30443-3 10.1016/j.eururo.2018.06.018 Long-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) is a standard treatment for patients with localized high-risk prostate cancer (HRPC). However (...) combined with RT can potentially be reduced to 18 mo in selected men without compromising survival or QoL. Thus, 18 mo of ADT appears to represent a valid option in HRPC. In this study, we report outcomes from high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 mo of androgen deprivation therapy. There was no difference in survival between the two groups, with the 18-mo group experiencing a better quality of life. Copyright © 2018 European Association of Urology. Published

EvidenceUpdates2018

28. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment 30028657 2018 09 12 1527-7755 36 25 2018 Sep 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide (...) Treatment. 2639-2646 10.1200/JCO.2018.77.9827 Purpose Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO ( ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis using a randomized, double-blind, placebo-controlled design. Patients and Methods In period one, men with chemotherapy-naïve metastatic castration-resistant prostate cancer received open-label enzalutamide 160 mg daily. Men with no prostate

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

29. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment

Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment

McGill TAU reports2018

30. Prostate cancer screening

Prostate cancer screening Top results for prostate cancer screening - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostate cancer screening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection

Trip Latest and Greatest2018

31. Prostate cancer

Prostate cancer Top results for prostate cancer - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostate cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

32. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Adding multiparametric MRI as an initial test prior to prostate biopsy can reduce the proportion of men having unnecessary biopsies and improve the detection of clinically significant prostate cancer. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . Louise Clare Brown 1 , Hashim U Ahmed 2, 3, * , Rita Faria 4

NIHR HTA programme2018

33. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 29624463 2018 06 15 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After (...) Radical Prostatectomy: SWOG S9921. 1498-1504 10.1200/JCO.2017.76.4126 Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason

EvidenceUpdates2018

34. Prostate cancer

Prostate cancer Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing

Trip Evidence Maps2018

35. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. BACKGROUND: Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level (...) . METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo once daily. The primary end point was metastasis-free survival (defined as the time from randomization to radiographic progression or as the time to death without radiographic progression). RESULTS: A total

NEJM2018

36. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline 29608397 2018 05 16 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 1521-1539 10.1200/JCO.2018.78.0619 Purpose This clinical (...) practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Methods Standard therapy for newly diagnosed metastatic prostate cancer has been ADT alone. Three studies have compared ADT alone with ADT and docetaxel, and two studies have compared ADT alone with ADT and abiraterone. Results Three prospective randomized studies (GETUG-AFU 15, STAMPEDE

EvidenceUpdates2018

38. Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer

Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2018

39. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.

Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. 29561693 2018 06 16 1527-7755 36 18 2018 Jun 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. 1823-1830 10.1200 (...) /JCO.2017.75.5371 Purpose To compare the toxicities and cost of proton radiation and stereotactic body radiotherapy (SBRT) with intensity-modulated radiotherapy (IMRT) for prostate cancer among men younger than 65 years of age with private insurance. Methods Using the MarketScan Commercial Claims and Encounters database, we identified men who received radiation for prostate cancer between 2008 and 2015. Patients undergoing proton therapy and SBRT were propensity score-matched to IMRT patients

EvidenceUpdates2018

40. Primary cryotherapy for localised or locally advanced prostate cancer.

Primary cryotherapy for localised or locally advanced prostate cancer. BACKGROUND: Traditionally, radical prostatectomy and radiotherapy with or without androgen deprivation therapy have been the main treatment options to attempt to cure men with localised or locally advanced prostate cancer. Cryotherapy is an alternative option for treatment of prostate cancer that involves freezing of the whole prostate (whole gland therapy) or only the cancer (focal therapy), but it is unclear how effective (...) this is in comparison to other treatments. OBJECTIVES: To assess the effects of cryotherapy (whole gland or focal) compared with other interventions for primary treatment of clinically localised (cT1-T2) or locally-advanced (cT3) non-metastatic prostate cancer. SEARCH METHODS: We updated a previously published Cochrane Review by performing a comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE), clinical trial registries (ClinicalTrials.gov, World Health Organization International Clinical Trials

Cochrane2018